Llibre RJ, Gutiérrez HRF

Idioma: Español
Referencias bibliográficas: 24
Paginas: 378-387
Archivo PDF: 200.83 Kb.

RESUMEN

La demencia es la primera causa de discapacidad en adultos mayores y la mayor contribuyente de dependencia, sobrecarga económica y estrés psicológico en el cuidador, sin embargo, aún no recibe la misma prioridad que otras enfermedades crónicas no trasmisibles, como las enfermedades cardiovasculares y el cáncer, que tienen un mayor impacto en la mortalidad. Se abordan aspectos relacionados con la prevalencia y el incremento del número de personas con demencia en América Latina y el Caribe para el 2030, su impacto y cómo la prevención de los factores de riesgo, con una perspectiva del curso de la vida desde la concepción y la vida intrauterina hasta la edad tardía y además, un enfoque multifactorial, pudieran potencialmente conducir a una reducción del número de enfermos. Un mayor énfasis en la prevención y un amplio acceso a la educación, mejores condiciones socioeconómicas, estilos de vida saludables y control de los factores de riesgo cardiovasculares, es una alternativa viable y sostenible para reducir el impacto creciente de las demencias en la sociedad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. World Health Organization. Dementia: A public health priority. Geneva: WHO; 2012 [cited 2012 Jun 5] Available from: http://www.who.int/mental_health/publications/dementia_report_2012

2. Sousa RM, Ferri CP, Acosta D, Albanese E, Guerra M, Huang Y, et al. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet. 2009;374(9704):1821-30.

3. Prince M, Guerchet M, Prina M. Policy Brief for Heads of Government: The Global Impact of Dementia 20132050. London: Alzheimer's Disease International (ADI); 2013 [cited 2013 Dec 20]. Available from: http://www.alz.co.uk/research/GlobalImpactDementia2013.pdf

4. Prince M, Acosta D, Ferri CP, Guerra M, Huang Y, Llibre Rodriguez JJ, et al. Dementia incidence and mortality in middle income countries, and associations with age, sex, socioeconomic position and indicators of cognitive reserve. A 10/66 Dementia Research Group population-based cohort study . Lancet. 2012;380 (9836):50-8. EPub 2012 May 23. doi:10.1016/S0140-6736(12)60399-7

5. Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Martin P. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet. 2008;372: 46474. EPub 2008 July 28. doi: 10.1016/S0140- 6736(08)61002-8

6. Sousa RM, Ferri CP, Acosta D, Guerra M, Huang Y, Ks J, et al. The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: a 10/66 Dementia Research Group population-based survey. BMC Geriatr. 2010;10(1):53.

7. Beaglehole R, Epping-Jordan J, Patel V, Chopra M, Ebrahim S, Kidd M, et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet. 2008;372(9642):940-9.

8. Kuh D, Ben-Shlomo Y, Lynch J, Hallqvist J, Power C. Life course epidemiology. J Epidemiol Comm Health. 2003;57:778-83. PubMed: 14573579.

9. Hughes T, Ganguli M. Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Curr Psychiatry Rev. 2009;5(2):7392.

10. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137-52. Epub 2011 Feb 8. doi:10.1038/nrneurol.2011.2

11. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377:101931.

12. Lee Y, Back JH, Kim J. Systematic review of health behavioural risks and cognitive health in older adults. Int Psychogeriatr. 2010;22:17487.

13. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-28.

14. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530-38.

15. Farlow MR. Alzheimer's disease. Continuum Lifelong Learning Neurol. 2007;13(2):3968.

16. Manton KC, Gu XL, Ukraintseva SV. Declining prevalence of dementia in the U.S. elderly population. Adv Gerontol. 2005;16:30-7.

17. Langa KM, Larson EB, Karlawish JH. Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? Alzheimers Dement. 2008;4:134-44.

18. Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78:1456-63.

19. Qiu C, von Strauss E, Bäckman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80:1888-94.

20. Matthews FE, Arthur A, Barnes LE. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405-12.

21. Larson EB, Yaffe K, Langa K. Perspective. New Insights into the Dementia Epidemic. New Engl J Med. 2013;369(24):2275-7. Epub 2013 Nov 27. doi:10.1056/NEJMp1311405

22. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization [review]. Circulation. 2001;104(22):2746-53.

23. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593.

24. Reisberg B, Doody R, Stoffler A. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-41.